Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions-Reference-Cited by-同舟云学术

Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions

Published:2012-01 Issue:1 Volume:8 Page:37-54
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Shen Xinglei¹,Zaorsky Nicholas G¹,Mishra Mark V¹,Foley Kathleen A²,Hyslop Terry³,Hegarty Sarah³,Pizzi Laura T⁴,Dicker Adam P¹,Showalter Timothy N⁵

Affiliation:

1. Department of Radiation Oncology, Kimmel Cancer Center & Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA

2. Thomson Reuters Healthcare, Cambridge, MA, USA

3. Division of Biostatistics, Department of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA

4. School of Pharmacy, Thomas Jefferson University, Philadelphia, PA, USA

5. Kimmel Cancer Center & Jefferson Medical College, Thomas Jefferson University, 111 S 11th Street, Bodine Center for Cancer Treatment, Philadelphia, PA 19107, USA.

Abstract

Comparative effectiveness research aims to help clinicians, patients and policymakers make informed treatment decisions under real-world conditions. Prostate cancer patients have multiple treatment options, including active surveillance, androgen deprivation therapy, surgery and multiple modalities of radiation therapy. Technological innovations in radiation therapy for prostate cancer have been rapidly adopted into clinical practice despite relatively limited evidence for effectiveness showing the benefit for one modality over another. Comparative effectiveness research has become an essential component of prostate cancer research to help define the benefits, risks and effectiveness of the different radiation therapy modalities currently in use for prostate cancer treatment.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon.11.131

Reference141 articles.

1. IOM (Institute of Medicine).Initial National Priorities for Comparative Effectiveness Research. National Academies Press, Washington, DC, USA (2009).

2. Can it work? Does it work? Is it worth it?

3. The Promise of Comparative Effectiveness Research

4. Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolution of brachytherapy for prostate cancer;Nature Reviews Urology;2017-06-30

2. A comparison of robotic arm versus gantry linear accelerator stereotactic body radiation therapy for prostate cancer;Research and Reports in Urology;2016-08

3. Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer;Cancer Treatment Reviews;2016-07

4. Why do patients regret their prostate cancer treatment? A systematic review of regret after treatment for localized prostate cancer;Psycho-Oncology;2015-03-01

5. Is robotic arm stereotactic body radiation therapy ‘virtual high-dose rate brachytherapy’ effective for prostate cancer? An analysis of comparative effectiveness using published data;Expert Review of Medical Devices;2014-12-25